Background. Giardia intestinalis is the most commonly reported human intestinal parasite in the United States. Increased incidence of chronic gastrointestinal complaints has been reported after some giardiasis outbreaks. We examined the relationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.
Giardia intestinalis (also known as Giardia lamblia and Giardia duodenalis; hereafter Giardia) is the most commonly reported human intestinal parasite in the United States, with approximately 20 000 cases reported per year and approximately 1.2 million cases estimated to occur per year [1] [2] [3] . This parasite causes giardiasis, typically characterized by diarrhea, abdominal cramps, bloating, malabsorption, and weight loss; asymptomatic infection also occurs [1, 3] . Giardiasis results from the ingestion of Giardia cysts through the consumption of fecally contaminated food or water or person-to-person transmission [1, 3] and is the most common pathogen-specific diagnosis received by travelers returning to the United States [4] .
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder, characterized by abdominal pain and altered bowel habits occurring at least 3 days per week in the previous 3 months, in which the evaluation for chronic enteric infection and underlying alternate gastrointestinal disease proves unrevealing [5, 6] . Seven percent of persons worldwide are estimated to have IBS [7] . Acute gastroenteritis has been associated with the subsequent onset of IBS symptoms in some patients, known as postinfectious IBS (PI-IBS) [8, 9] . Postinfectious IBS has been defined as the onset of new IBS symptoms as defined by Rome III Criteria for IBS [6] in an individual without prior IBS following an acute gastrointestinal infection characterized by ≥2 of the following: fever, vomiting, diarrhea, or a stool culture positive for an infectious agent [8, 10, 11] . The incidence of PI-IBS after any gastrointestinal infection has been reported to range 3%-36% [11] [12] [13] [14] [15] , depending on the infecting organism [15] . One meta-analysis showed the odds of developing IBS are increased 6-fold after acute gastrointestinal infection [16] .
Although PI-IBS has been well documented for bacterial diarrheal illnesses [8, 11, 14, [16] [17] [18] , less is known about its association with Giardia infection. Giardiasis is generally self-limited in healthy individuals, yet increased incidence of chronic gastrointestinal symptoms has been reported after some outbreaks, suggesting long-term sequelae of giardiasis [19] [20] [21] . A follow-up study using self-reported symptom data 3 and 6 years after a giardiasis outbreak in Norway showed that patients with giardiasis had 3.4 times higher risk of IBS than controls who had not fallen ill as part of the outbreak [20, 21] .
An ecological study in Colombia also found incidence rates of giardiasis and IBS were associated [22] .
To further explore the possible association between giardiasis and PI-IBS in a broader patient population, we used a large US health insurance database to assess the longitudinal relationship between giardiasis diagnosis and IBS diagnosis using a retrospective cohort study design.
METHODS
In this study, we used longitudinal data from the Truven Health Analytics MarketScan Commercial Claims and Encounters Database [23] . MarketScan captures medical billing data, including inpatient and outpatient healthcare encounters, diagnoses, diagnostic tests and procedures, prescription medication, costs, and demographic information for >45 million people in the United States covered by employer-sponsored private health insurance (employees, retirees aged <65 years, former employees, and spouses and dependents of these individuals). Because no interaction or intervention with human subjects occurred and no personally identifiable information was used, collected, or transmitted in the course of this analysis of previously collected data, the analysis was not considered human subjects research (as defined in the US Department of Health and Human Services Code of Federal Regulations Title 45 part 46 [24] ) subject to institutional review board review.
We conducted a retrospective cohort study over the 5-year period from 1 January 2006 through 31 December 2010 to assess the association between giardiasis diagnosis and subsequent diagnosis of IBS or persistent gastrointestinal symptoms. We identified patients who incurred a claim that was assigned the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 007.1 during the study period (the giardiasis cohort).
This group with giardiasis was matched with a comparison group of persons without a giardiasis diagnosis (the unexposed or giardiasis-free cohort). Unexposed persons had health insurance (although might not have had any claims while enrolled in health insurance) and were matched with exposed people on sex, 5-year age group, and length of enrollment in the database. Five unexposed people were matched to each exposed person and assigned an index date that corresponded to the length of time from month of enrollment to index date of giardiasis. Our initial matched cohort included 36 336 people (6056 people with giardiasis diagnoses and 30 280 people without giardiasis diagnoses). We excluded people with an IBS diagnosis before their index date (n = 408), persons with ≤90 days of enrollment before their index date (n = 6570), and persons with ≤90 days of follow-up after their index date (n = 5721) to allow for sufficient time to observe prior healthcare utilization as well as diagnosis of outcome given that diagnosis of IBS requires a symptom duration of ≥3 months [6] . A total of 12 738 people were excluded for having ≥1 exclusion criteria (criteria were not mutually exclusive) or for being matched to an excluded exposed person.
We extracted data for age at index date, sex, and geographic region of residence [25] for all individuals. Depression (ICD-9-CM codes 296.2, 296.3, 296.82, 300.4, and 311), anxiety (ICD-9-CM codes 293.84, 300.00, 300.02, 300.09), and smoking (ICD-9-CM codes 305.1, V15.82) were selected as covariates of interest because of their previously reported association with PI-IBS [15, 16, 26] , and human immunodeficiency virus (HIV; ICD-9-CM codes 042, 079.53, V08) was considered because we hypothesized that a compromised host immune status could predispose an individual to prolonged or additional illness. Because giardiasis rates differ by region of residence within the United States [1] , region of residence was selected as a covariate. Finally, we tallied outpatient visits ≥90 days prior to the index date for all individuals as a proxy for healthcare utilization prior to giardiasis diagnosis to be considered as a potential confounder because persons with more healthcare visits in general could have an increased likelihood of receiving any diagnosis, including a diagnosis of IBS. This time frame was chosen to exclude visits possibly related to the giardiasis diagnosis. We calculated a healthcare utilization rate by dividing the number of outpatient visits by the number of months of enrollment and categorized the rates into quartiles for analysis. We considered patients to have received a laboratory diagnostic test for giardiasis if they had a procedure code claim for ova and parasite exam, direct fluorescent antibody test, enzyme immunoassay, immunofluorescent assay, or a cartridge test within 30 days before or after their first giardiasis diagnosis.
We established 3 outcome measures to examine IBS and persistent gastrointestinal symptoms ( Table 1) . Outcome 1 was defined as at least 1 ICD-9 diagnosis of IBS. Outcome 2 was defined as ≥2 diagnoses of gastrointestinal symptoms or IBS diagnosis occurring ≥3 months apart, given the duration requirement for a diagnosis of IBS. Outcome 3 was defined as IBS diagnosis in the absence of alternate explanations of IBS symptoms [27, 28] . Persons with alternate explanations of symptoms were included in the analysis and considered not to have IBS.
We assessed differences in proportions for demographic, outcome, and confounding variables by giardiasis exposure status. Time at risk of developing an outcome was defined as the number of days between the index date and the date on which the outcome criterion was documented (ie, date of IBS diagnosis for outcomes 1 and 3 and date of the first visit fulfilling definition of outcome 2) or end of enrollment (ie, censored observation).
Using the sum of all person-time at risk, we calculated 1-, 2-, and 3-year incidence rates for each outcome measure by giardiasis exposure status. To examine the association between giardiasis and IBS while controlling for confounding and preserving the match between exposed and unexposed persons, we developed stratified (by matched exposed/unexposed group) Cox proportional hazard models. For these models specifically, we only included outcomes that were first documented at least 90 days after the index date because IBS is a chronic condition and definitions of IBS require a symptom duration of ≥3 months [6] . Persons with outcomes documented within 90 days of the index date were excluded from this analysis. Individuals were followed until outcome, censorship, or end of the study period. Sex and age were controlled by matching. Covariates considered for inclusion in a multivariable model included geographic region, healthcare utilization quartile, anxiety, depression, smoking, and documented HIV infection. Covariates were selected using backward elimination (P < .10 to stay), followed by evaluating whether excluded variables changed the estimate for giardiasis-PI-IBS association by >10%. For each covariate, we tested an interaction term to assess whether variables associated with the outcome criterion differed between individuals with a diagnosis of giardiasis and those without. Adjusted models were also stratified by age group (<20 years, ≥20 years) and sex. The proportional hazards assumption was assessed by examining survival plots and evaluating correlations between Schoenfeld residuals and ranked survival times. All data management and analyses were conducted using SAS version 9.3.
RESULTS
The matched cohort included 3935 persons with giardiasis and 19 663 persons without giardiasis. Demographics, comorbidities, and healthcare utilization rates are summarized in Table 2 . Age, sex, and enrollment length cohort characteristics reflect the matched design. Median enrollment length was 36 months (range = 7-60 months). Persons with giardiasis had higher prevalence of anxiety, depression, and smoking and higher prediagnosis healthcare utilization rates compared with persons without giardiasis.
The crude 1-year incidence rates of IBS diagnosis (outcome 1) were 37.7 per 1000 person-years in persons with giardiasis and 4.4 per 1000 person-years in persons without giardiasis (Table 3) . Similarly, the 1-year incidence rates for outcomes 2 and 3 were higher in persons with giardiasis than in persons without giardiasis. The crude 2-year and 3-year incidence rates were somewhat lower than the 1-year incidence rates for persons with giardiasis but were similar for persons without giardiasis. For example, for outcome 1, the crude 2-year incidence rate was 30.7 per 1000 person-years and the 3-year incidence rate was 27.5 per 1000 person-years in persons with giardiasis, and both the 2-year and 3-year incidence rates were 4.4 per 1000 person-years in persons without giardiasis. Incidence rates for outcomes 2 and 3 followed a similar pattern (not shown).
The unadjusted hazard ratio (HR) for outcome 1, IBS diagnosis, was 4.8 (95% confidence interval [CI] = 3.6-6.4) ( Table 4) . This was attenuated slightly after adjusting for anxiety, depression, and healthcare utilization to 3.9 (95% CI = 2.9-9.4). Geographic region of residence, smoking, and HIV status were not selected in the final model. The adjusted hazard ratios for outcomes 2 and 3 had similar magnitude and significance (HR = 4.2, 95% CI = 3.7-4.8; HR = 3.5, 95% CI = 2.5-4.9, respectively). Excluding 2137 persons with giardiasis who did not have evidence of receiving a diagnostic test led to similar results for outcomes 1 and 3 (HR = 3.8, 95% CI = 2.4-96.2; HR = 3.5, 95% CI = 2.0-96.0) and a somewhat stronger association for outcome 2 (HR = 4.8, 95% CI = 3.9-95.8).
For outcomes 1 and 3, no interaction terms tested in the models were statistically significant. For outcome 2, there was a statistically significant interaction between healthcare utilization and giardiasis, such that the hazard ratio for persons with giardiasis was of a greater magnitude in the lower 3 quartiles of healthcare utilization than in the highest quartile (Table 5 ). In analyses stratified by sex and age group, the hazard ratios were consistently higher for males subjects than female subjects and in persons aged <20 years than in persons aged ≥20 years. For outcomes 1 and 3, the confidence intervals of the 2 strata overlapped, but for outcome 2, the confidence intervals did not overlap.
DISCUSSION
In this longitudinal cohort study among a large, US health insurance population, we found that individuals diagnosed with giardiasis were approximately 4 times more likely than those without giardiasis to have subsequent IBS diagnosis ≥90 days after their giardiasis diagnosis. This association was slightly attenuated but persisted after accounting for confounding effects of comorbid anxiety, depression, and healthcare utilization. Further, the association was seen not only for diagnosis of IBS but also for a broader outcome measure representing longer-term gastrointestinal symptoms as well as a more specific outcome measure, excluding alternate diagnostic explanations for symptoms. These findings using health insurance billing data lend further support to a link between giardiasis and long-term gastrointestinal complaints suggested by outbreak follow-up studies. Observational follow-up using self-reported symptom data was conducted following a large, waterborne outbreak of Giardia gastroenteritis in Bergen, Norway, in 2004 that resulted in approximately 5000 cases of giardiasis [29, 30] . Three years c Quartiles were based on entire cohort prior to application of exclusions specific to this analysis.
after acute giardiasis, the prevalence of IBS was 46%, compared with 14% in a control group, for an adjusted relative risk of 3.4 [21] . Six years after acute giardiasis, the prevalence of IBS in the group with prior giardiasis was 39%, compared with 12% in the control group, for a similar adjusted relative risk of 3.4 [20] . Our longitudinal cohort analysis using a large health insurance database allowed us to ask a similar research question in a broader population in a second country using a different study design. The use of the health insurance billing data provides a large number of giardiasis cases and a very large pool of persons without giardiasis to match for comparison. In addition, the insurance database is presumed to include mainly sporadic cases (given that <2% of reported cases are associated with known outbreaks and not all diagnosed cases are reported [1] ), extending the findings of outbreak follow-up studies to a population that includes sporadic cases. Methodologically, because outcome information is available for all persons without their having to choose to participate in a research study, using an insurance database overcomes the potential for recall bias inherent in survey designs. Our study design further adds the ability to investigate comorbidities and healthcare utilization as potential confounders. Our findings support the suggestion in the literature that the magnitude of PI-IBS following giardiasis could be large: based on the 1-year incidence rates calculated in this study, if 1000 patients were followed for 1 year after being diagnosed with giardiasis, 37 would be diagnosed with IBS, and 170 would have ongoing gastrointestinal symptoms resulting in multiple office visits. Although the proportion of patients experiencing chronic symptoms we observed is smaller than that observed following the Bergen outbreak (39% 6 years after the outbreak [20] ), potentially because of differences in study population, methodology, outbreak strain, or dose, it is nonetheless substantial. Irritable bowel syndrome and chronic gastrointestinal symptoms impact quality of life [7] . They are also likely to be costly, as patients being treated for IBS and other chronic symptoms likely incur additional office visits and testing and may require medication and the pursuit of treatment, including dietary restriction [31] , on a long-term basis.
The pathogenesis of PI-IBS is poorly understood and might differ depending on the pathogen causing the preceding infection [32] . Different mechanisms have been proposed, including persistent intestinal inflammation due to inability of the host to contain the inflammatory reaction [8, 11, 15, 26] , chronic mucosal immunologic dysregulation [15, 18] , altered intestinal flora [11, 26, 33] , increased intestinal permeability [11, 18, 26, 33] and motility [18] , muscle hypercontractility [11] , and visceral hypersensitivity [11] . Further, the relationship between giardiasis and PI-IBS may be complex. D' Anchino [34] studied 100 symptomatic giardiasis patients and found 82 of them had previously identified IBS, suggesting symptoms attributed to giardiasis may in fact result from preexisting IBS exacerbated by Giardia infection. In other words, the possibility exists that postinfectious IBS may in fact be related to preexisting IBS. Abbreviations: CI, confidence interval; IBS, irritable bowel syndrome. a Outcome 1 model was adjusted for anxiety, depression, and healthcare utilization. Outcome 2 and 3 models were adjusted for anxiety and healthcare utilization.
In this study, we excluded people with preexisting IBS documented in their billing records; however, we cannot rule out the possibility that they had undiagnosed IBS or a diagnosis before enrollment. A combination of host risk factors, genetic factors, pathogen factors, and host-pathogen interaction might serve as a basis for risk of PI-IBS [17, 32] . Our finding of a stronger association between giardiasis and IBS in the younger age stratum is consistent with several studies that identified younger age as a risk factor for PI-IBS [8, 16] . Whereas we found that the association between giardiasis and IBS was stronger in male subjects, several studies found PI-IBS (not specific to giardiasis) to be more common in female subjects [33, 35] . The Norwegian giardiasis outbreak follow-up studies [21, 29] found a slightly higher prevalence of IBS among female subjects in both the group with giardiasis and the group without, but female sex was not an effect modifier for IBS after giardiasis.
The observed association between diagnosis of giardiasis and subsequent diagnosis of IBS in this study was slightly attenuated but persisted after adjusting for depression, anxiety, and healthcare utilization. We found that healthcare utilization partially confounded the association between giardiasis and IBS. In addition, we identified a statistically significant interaction: persons in the highest quartile of healthcare utilization rates had a lower-magnitude, but still significant, association between giardiasis and persistent gastrointestinal symptoms. However, because the risk of persistent symptoms was elevated in all strata of healthcare utilization, the interaction may have no clinical significance. In prior work, an association between high healthcare utilization and IBS has been suggested [36] but not consistently found [26] .
Diagnostic criteria for IBS, such as Rome I, Rome II, Rome III, and Manning, have ensured homogeneity of patient population for research purposes, although their use in clinical practice is limited [8] . Unfortunately, there is no laboratory test to diagnose this syndrome, and physicians may use varying criteria for diagnosis. The diagnostic criteria incorporate time spans of months into the definitions, further complicating diagnosis, and patients with IBS could go undiagnosed for long periods of time. We attempted to account for underdiagnosis using outcome 2, which included repeated visits for gastrointestinal symptoms consistent with IBS, including abdominal pain, diarrhea, or constipation. Far more people met criterion 2 in both groups, but the adjusted association between giardiasis and subsequent outcome remained similar. Although not all patients meeting criterion 2 have IBS, the results suggest that a large subset of giardiasis patients experience prolonged gastrointestinal symptoms.
Health insurance billing data differ from medical records. Although numerous prior works have used health plan administrative data and ICD-9 codes in research [27, [37] [38] [39] [40] , using ICD-9 codes as a proxy for disease is imperfect. Exposures and outcomes are included only if individuals have health insurance, if individuals choose to present to healthcare, if they are diagnosed [41, 42] , and if the billing code associated with their visit correctly reflects their diagnosis. This is particularly true for IBS diagnosis, which, as a diagnosis of exclusion, can take months to investigate and rule out alternate diagnoses. Billing data do not reveal when a person first developed symptoms, only when the first healthcare visit with compatible symptoms in the diagnosis codes occurred. Furthermore, other disease processes may present similarly to and may be mistaken for IBS; we attempted to account for this using the more specific outcome 3. Finally, the choice to present for healthcare, and hence have a healthcare visit recorded, is likely driven by many factors. For example, in preliminary data analyses we found that persons enrolled in a health insurance plan for short periods of time, such as 1 month, or nearing the beginning or end of enrollment were apt to have more healthcare visits than others, presumably making the most of their health insurance while they have it. Taking this into consideration, we restricted analysis to individuals who had ≥90 days of enrollment prior to cohort entry date and adjusted for healthcare utilization rate. We relied on the same administrative data source for the potential confounders anxiety and depression; a validation study found these diagnoses to have moderate agreement with both the Composite International Diagnostic Interview and self-reported physician-diagnosed anxiety or depression [43] . Stratified models for outcome 1 were adjusted for anxiety, depression, and healthcare utilization. Stratified models for outcomes 2 and 3 were adjusted for anxiety and healthcare utilization. Results for outcome 2 that are stratified by age and sex do not incorporate the giardia × healthcare utilization interaction.
Abbreviations: CI, confidence interval; IBS, irritable bowel syndrome.
Nonetheless, using health services databases such as MarketScan allows investigators to follow a large population of patients prospectively over multiple years and, through a unique patient identifier, across services and time. The large number of persons included in databases such as these may improve the ability to generalize analysis results to a greater population. Further, recall biases that may affect results of survey-based studies are mitigated. MarketScan databases have been used in studies in a variety of different areas from chronic obstructive pulmonary disease to ischemic colitis, often to investigate risk [28, [44] [45] [46] .
Identifying an association between diagnosis of giardiasis and subsequent diagnosis of IBS in a large US health insurance population opens the door to opportunities to further explore this relationship. Several additional factors have been associated with PI-IBS, which we were not able to consider in this study given our data source: duration and severity of the initial gastrointestinal illness [8, 11, 14] , genetic predisposition [14] , features of the pathogen and host-pathogen interaction [11, 46] , and as discussed, possible preexisting IBS that was either undiagnosed or not evident in the MarketScan data [34] . Methods similar to those in this study could be used to further investigate associations between giardiasis and nongastrointestinal outcomes, including chronic fatigue [21] . It is unknown what, if any, effect prompt diagnosis and treatment with antiprotozoal medications has on the risk of developing PI-IBS. Future research could explore possible risk factors for PI-IBS among giardiasis patients (including delayed diagnosis or treatment), the pathogenicity of different Giardia assemblages (or genetic variants) [47] , and the pathophysiology of PI-IBS itself and, in the longer term, may aid in patient prognosis, treatment, and the development of new prevention strategies.
